Biomarker ID | 1886 |
PMID | 30623593 |
Year | 2018 |
Biomarker | Isoform 2 of Eukaryotic translation initiation factor 2â€alpha kinase 4; Keratin type I cytoskeletal 10; SCO†spondin; Serum amyloid Pâ€component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain Vâ€IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal; |
Biomarker Basis | Concentration Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein Aâ€I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4 (0.2 fold); Interâ€alphaâ€trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain Vâ€III region BRO (0.2 fold); Ig gammaâ€2 chain C region (0.2 fold); Ig gammaâ€3 chain C region (0.2 fold);] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) |
Type of Biomarker | Diagnostic |
Cohort | Serum samples from African American and Caucasian PCa patients and matched healthy donors were collected after patients’ consents |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | mass spectrometry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |